Similarly, A.C. Matin’s group constructed an engineered EV capable of targeting HER2-positive breast cancer cells, encapsulating HChrR6 mRNA and prodrug CNOB (C16H7CIN2O4) to reach tumor cells, using HChrR6 to convert the CNOB activation into the cytotoxic drug MCHB (C16H9CIN2O2) [131,132]. The gene discussed is ERBB2; the disease is neoplasm.